International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

# Novel Drug Delivery Systems: Advances & Challenges

**Mr. Utkarsh Pathak[1], Mr. Vivek Vashistha[2], Mr. Sudhir Arora[3]**

[1]B.Pharm Student, Department of Pharmaceutics, IIMT College of Pharmacy
[2,3]Assistant Professor, Department of Pharmaceutics, IIMT College of Pharmacy

**Abstract**

The field of pharmaceutical sciences has undergone a dramatic shift with the rise of Novel Drug Delivery Systems (NDDS), which harness advanced technologies to tackle persistent issues in drug administration, treatment effectiveness, and patient adherence. These cutting-edge platforms—such as nanoparticle carriers, liposomal vesicles, microneedle patches, and stimuli-responsive polymers—have revolutionized drug delivery by improving precision, enabling controlled release, and boosting bioavailability [1, 2, 3]. For example, nanotechnology takes advantage of the enhanced permeability and retention (EPR) effect to direct chemotherapy drugs specifically to tumors, reducing harmful side effects and enhancing cancer treatment outcomes [1,14]. Meanwhile, liposomal systems, developed in the 1960s, safely encase both water-soluble and fat-soluble drugs within lipid layers. PEGylated versions like Doxil have proven especially valuable in cancer care, lowering heart-related risks without sacrificing effectiveness [2, 15, 31]. Another breakthrough is microneedle technology, where tiny, painless patches (just 100–1000 micrometers) deliver drugs through the skin. This approach has transformed vaccine and insulin administration, making treatments more comfortable and increasing patient cooperation [3, 10, 40]. Additionally, smart polymers and hydrogels—which react to changes in pH, temperature, or glucose—allow for dynamic drug release, opening new doors for personalized medicine in chronic conditions like diabetes [11, 35, 112].

NDDS are making waves across multiple medical fields, from cancer and diabetes to neurological and infectious diseases. In oncology, nanoparticles and antibody-drug conjugates (ADCs) home in on tumor-specific markers, delivering potent drugs with unmatched accuracy—leading to better survival rates and fewer side effects [5, 14, 49]. For diabetes, innovations like glucose-sensitive microneedles and injectable hydrogels automate insulin delivery, mimicking the body's natural responses and reducing the need for frequent injections [106, 107, 109]. In neurology, engineered nanoparticles equipped with targeting molecules can cross the blood-brain barrier (BBB), offering new hope for Alzheimer's and Parkinson's treatments. Intranasal delivery systems also show promise by using olfactory pathways for rapid drug absorption [67, 70]. Infectious disease treatment has also benefited, with liposomes and nanoparticles improving drug solubility and effectiveness against resistant pathogens like tuberculosis and HIV [77, 78]. Moreover, microneedle vaccines enhance immune responses by directly engaging skin-based immune cells, presenting a scalable solution for mass immunization [79, 80]. Despite their potential, NDDS face major hurdles in clinical translation. Manufacturing complexities—such as ensuring nanoparticle uniformity, sterility, and scalability—drive up costs significantly [85, 87, 88]. Safety remains another concern, as some nanomaterials may trigger immune reactions or toxicity, requiring extensive testing before approval [55, 56, 96]. Regulatory systems, still tailored for traditional drugs, struggle to classify

NDDS as combination products, leading to delays and higher development expenses [102, 104, 108]. High costs further limit access, particularly in low-income regions where advanced therapies like Doxil and Abraxane remain out of reach [113, 115]. Storage and distribution challenges, such as the need for refrigeration, also hinder deployment in areas with poor infrastructure [1, 8]. The future of NDDS depends on merging emerging technologies to overcome current limitations. Wearable biosensors and AI-driven systems could enable real-time drug adjustments, as seen in next-gen glucose-responsive insulin delivery [6, 7]. Bioinspired carriers, like exosome-based systems, may offer safer, more efficient alternatives to synthetic nanoparticles [149, 150]. Sustainable production methods, including biodegradable polymers (e.g., chitosan) and eco-friendly synthesis, could make NDDS more affordable and environmentally sound [28, 91]. Success will require cross-sector collaboration—uniting researchers, industry leaders, and policymakers to refine manufacturing, update regulations, and expand global access [4, 92, 146]. By addressing these challenges, NDDS could reshape modern medicine, merging cutting-edge science with patient-focused care to improve outcomes worldwide [93, 117]. This review highlights the latest NDDS advancements, their clinical potential, and the barriers to adoption. These systems address key shortcomings of traditional drug delivery—such as poor solubility, rapid elimination, and off-target effects—while paving the way for precision medicine [8, 118]. Exploring future innovations like digital integration, bioinspired designs, and green manufacturing can drive further progress, ensuring NDDS fulfill their promise in transforming healthcare [11, 147].

**Keywords:** Novel drug delivery systems, nanotechnology, liposomes, microneedles, smart polymers, targeted therapy, controlled release, biocompatibility, regulatory challenges, digital health, bioinspired carriers, sustainable production

## 1. Introduction

The field of pharmaceutical sciences has undergone a transformative shift from conventional drug delivery methods like oral tablets and injections to advanced Novel Drug Delivery Systems (NDDS), which significantly enhance therapeutic precision, efficacy, and patient compliance [1, 8, 118]. Traditional approaches often suffer from drawbacks such as poor solubility, rapid clearance, and non-specific distribution, leading to suboptimal treatment outcomes, particularly in chronic diseases like cancer, diabetes, and neurological disorders [2, 5, 8, 65]. NDDS overcome these limitations by employing cutting-edge technologies—including nanotechnology, liposomal carriers, microneedles, and stimuli-responsive polymers—to enable targeted delivery, controlled release, and improved bioavailability, thereby revolutionizing modern medicine [3, 4, 5, 9, 11]. Over the past century, drug delivery systems have evolved from basic oral formulations in the early 1900s to today's intelligent, responsive platforms [118]. The mid-20th century saw the introduction of injections, followed by liposomes in the 1960s, which allowed for targeted drug delivery with reduced toxicity [15, 29]. Subsequent innovations like transdermal patches (1980s), nanoparticles (2000s), and smart polymers (recently) have further refined precision medicine, adapting drug release to physiological conditions such as pH or glucose levels [3, 5, 18, 35, 112]. These advancements have profound clinical implications: nanotechnology leverages the enhanced permeability and retention (EPR) effect to improve cancer therapy, microneedles enable painless insulin delivery for diabetes, and intranasal nanoparticles facilitate drug transport across the blood-brain barrier (BBB) for neurological treatments [1, 5, 10, 70]. NDDS also enhance the delivery of biologics, protecting fragile molecules like proteins and nucleic acids while ensuring effective targeting [8, 9]. Despite their

promise, NDDS face challenges in clinical translation, including high production costs, complex manufacturing, biocompatibility concerns, and regulatory hurdles [7, 55, 56, 85, 102, 104]. Addressing these barriers requires interdisciplinary collaboration to optimize manufacturing, ensure safety, and align regulatory frameworks [4, 146]. This review examines the technological foundations, therapeutic applications, and challenges of NDDS, emphasizing their potential to surpass traditional drug delivery limitations and meet unmet medical needs [8, 117]. It also explores future innovations—such as digital integration, bioinspired designs, and sustainable manufacturing—to advance equitable, patient-centered healthcare solutions globally [6, 91, 149].

**Table 1: Evolution of Drug Delivery Systems**

| Time Period | Delivery System | Key Features | Advancements | References |
|---|---|---|---|---|
| Early 1900s | Conventional (e.g., Tablets) | Simple oral administration, systemic distribution | Basic delivery, limited control over release | [18] |
| Mid-1900s | Injections (e.g., Syringes) | Direct systemic delivery, rapid onset | Improved bioavailability, invasive method | [118] |
| 1960s–1980s | Liposomes | Encapsulation in lipid vesicles, biocompatibility | Targeted delivery, reduced toxicity | [15], [29] |
| 1980s–1990s | Transdermal Patches | Non-invasive, sustained release through skin | Enhanced patient compliance, steady dosing | [3] |
| 2000s–Present | Nanoparticles | Nano-scale carriers, targeted therapy | Precision targeting, controlled release | [5], [18] |
| 2010s–Present | Smart Polymers/Hydrogels | Stimuli-responsive (e.g., pH, temperature) | Intelligent release, personalized medicine | [35], [112] |

This review starts with the tech behind NDDS—like nanocarriers, liposomes, and microneedles—then looks at how they tackle specific illnesses, and wraps up with the roadblocks and what's next. By pulling together the latest breakthroughs and research, it aims to spark ideas on how NDDS could redefine pharmaceutical sciences.

## 2. Technological Foundations of Novel Drug Delivery Systems

The success of NDDS is underpinned by a diverse array of technologies that enable precise control over drug release, targeting, and pharmacokinetics. This section outlines the most prominent platforms driving innovation in drug delivery.

### 2.1 Nanotechnology-Based Drug Delivery

Nanotechnology is a pivotal innovation in Novel Drug Delivery Systems (NDDS), offering groundbreaking solutions for drug formulation and delivery [11]. Nanoparticles, typically 1–100 nanometers in size, encapsulate drugs, shielding them from degradation and enabling penetration through biological barriers like the blood-brain barrier (BBB) [12]. Common nanomaterials include polymeric

nanoparticles (e.g., PLGA), metallic nanoparticles (e.g., gold, silver), and carbon-based structures like graphene oxide [13]. The primary advantage of nanotechnology lies in targeted delivery, achieved by functionalizing nanoparticles with ligands such as antibodies or peptides, which bind specific cells, reducing off-target effects [14]. In cancer therapy, nanoparticles leverage the enhanced permeability and retention (EPR) effect to accumulate in tumors, enhancing the therapeutic index of drugs like doxorubicin [1, 15]. Additionally, stimuli-responsive nanoparticles, triggered by pH or temperature changes, enable controlled drug release at precise sites, improving efficacy [16]. For instance, pH-sensitive nanoparticles release payloads in acidic tumor microenvironments, sparing healthy tissues [19]. Nanotechnology also facilitates delivery of biologics, such as siRNA, protecting them from degradation and ensuring cellular uptake [9]. In neurological disorders, ligand-functionalized nanoparticles cross the BBB via receptor-mediated transcytosis, delivering therapeutics for Alzheimer's or Parkinson's [67]. However, challenges like cytotoxicity, immune responses, and complex manufacturing processes hinder scalability and clinical translation [21, 56, 87]. Advances in bioinspired nanoparticles, like exosome mimics, and green synthesis methods aim to enhance biocompatibility and affordability, promising broader applications in precision medicine [91, 149].




**Figure 1. Nanotechnology and targeted drug delivery: Schematic representation of a nano-drug delivery system encapsulated with active molecules and surface modified with different targeting moieties having both therapeutic and diagnostic abilities.[18]**

### 2.2 Liposomal Drug Delivery Systems

Liposomes are spherical vesicles of lipid bilayer which serve as cell-like structures are one of the greatest innovations in NDDS [17]. Liposomes were first introduced in the 1960's as a versatile carrier and have transformed to be able to encapsulate both hydrophilic and hydrophobic drugs [18]. They can biocompatible, biodegradable and efficiently mimic the cell membrane thus making them useful for delivering a vast range of therapeutic agents such as proteins, small molecules, and nucleic acids [19].

Depending on the drug's physicochemical properties, liposomes have the ability to incorporate drugs into their aqueous core or lipid bilayer [20]. The addition of PEG serves as passive immune evasion which reduces body clearance as they increase defence. Such stealth behaviour by the immune system enhances circulation time to accumulate in the targeted location [21]. This can be seen in the case of doxorubicin (e.g. Doxil) which is taken up by the PEGylated liposomal formulation for cancer therapy showing reduced cardiotoxicity of the drug without losing the intended effect[22]. Responding to external changes, like heat, light or changes in pH, the stimuli responsive technology provides the ability for liposomes to smartly release their cargo [23].

These "smart" liposomes hold promise for applications requiring precise temporal and spatial control of drug release, such as in the treatment of inflammatory diseases or infections [24]. Despite their advantages, challenges such as high production costs and potential instability during storage remain areas of active research [25].




**Figure 2. Structure of PEGylated liposome. Consist of a liquid suspension and size range from 80 to 90 nm. [33]**

### 2.3 Microneedle-Based Delivery Systems

Microneedles (MNs) offer a slick way to slip meds through the skin with barely a pinch, breaking past the stratum corneum without the ouch factor [26]. They're crafted from stuff like silicon, metals, or polymers that dissolve. Size-wise, they're tiny—ranging from 100 to 1000 micrometres [27]. MNs come in four Flavors based on how they're built: solid, coated, hollow, and dissolving, each with its own drug-dropping style [28]. They've caught eyes for easily delivering drugs, vaccines, and biologics into the skin's vessel-rich, immune-packed layers [29]. Take hyaluronic acid or polyvinyl alcohol ones—they melt away, releasing meds as they soak into the skin, no needle-pulling needed [30]. They're even shaking up diabetes care, swapping painful insulin jabs for painless pricks [31]. Plus, pairing them with microfluidics and sensors lets them track biomarkers live, opening doors for theragnostic [32]. Their ease of use and potential for self-administration make them particularly appealing for improving patient compliance, especially in resource-limited settings [33]. However, limitations such as restricted drug loading capacity and the need for precise manufacturing techniques pose challenges to their scalability [34].




**Figure 3. Types of microneedles and their corresponding drug delivery mechanisms,[151] licensed under CC BY 4.0.**

### 2.4 Smart Polymers and Hydrogels

Smart polymers and hydrogels are a class of responsive materials that have revolutionized NDDS through environment triggered drug delivery systems [35]. These materials can change their physical properties or chemical structure when an external stimuli temperature, pH or ionic strength is applied, which makes them suitable for controlled and site-specific delivery mechanisms [36]. For example, polymeric drugs such as poly(N-isopropylacrylamide) (PNIPAAm) are thermo-responsive and show phase shift above certain temperatures which results in controlled drug release from the system [37].

Hydrogels are indeed three-dimensional structures of hydrophilic polymers which possess the ability to swell with greater amounts of fluid containing water or drugs while maintaining their structural features, thereby serving as a drug reservoir [38]. Their adjustable attributes make them ideal for sustained release form such as ocular implants and wound dressings [39]. Other advancements include development of injectable hydrogels that solidify in situ which have non-invasive delivery systems for targeting deep tissues [40]. The application range of smart polymers and hydrogels is extended when used in conjunction with other NDDS platforms such as nanoparticles or liposomes allowing these systems to work as hybrids with enhanced functionality [41].

For example, pH-sensitive hydrogels have been employed in oral drug delivery to protect acid-labile drugs in the stomach and release them in the neutral environment of the intestines [42]. Similarly, glucose-responsive hydrogels have shown promise in insulin delivery systems, releasing insulin in response to elevated blood glucose levels [43].

Despite their potential, smart polymers and hydrogels face challenges related to biocompatibility, degradation rates, and the complexity of designing systems that respond reliably to physiological conditions [44]. Ongoing research aims to address these issues by developing bioinspired materials and improving fabrication techniques [45]. Together, these technological platforms—nanoparticles, liposomes, microneedles, and smart polymers—form the backbone of NDDS, enabling a wide range of therapeutic applications

## 3. Applications of Novel Drug Delivery Systems

The advancements in NDDS have translated into tangible benefits across various therapeutic areas. This section highlights key applications, demonstrating how these systems address unmet medical needs and improve patient outcomes.

### 3.1 Cancer Therapy

Cancer's still a top killer globally, pushing us to find smarter ways to make chemo drugs work better and safer [46]. New drug delivery systems (NDDS) have totally flipped the script in oncology, zeroing in on tumours with toxic drugs while dialling back damage to the rest of the body [47]. Tech like nanoparticles and liposomes taps into the EPR effect, piling up in tumours to blast them with meds and leave healthy stuff alone [48]. Take Abraxane—those albumin-wrapped paclitaxel nanoparticles juice up solubility and hit harder for breast and lung cancer folks [49]. Liposomal doxorubicin's another win, cutting heart risks tied to anthracycline treatments [50]. New tricks like antibody-drug conjugates (ADCs) and responsive nanoparticles crank precision up a notch [51]. ADCs pair antibodies with killer drugs, nailing cancer cells that flash specific markers [52]. Smart nanoparticles, meanwhile, drop their load in the tumour's acidic vibe, sharpening focus and trimming side hits [53]. These breakthroughs widen the sweet spot for cancer meds, boosting survival odds and life quality. Beyond chemo, NDDS are dipping into immunotherapy and gene tweaks—liposomes and nanoparticles haul immune boosters or nucleic acids like siRNA and mRNA to flip tumours defences or hush cancer genes [54]. It's exciting stuff, but getting it to patients means tackling immune dodging and slick cell delivery [55].




**Figure 4. The general mechanism of action of an antibody-drug conjugate (ADC), [152] Licensed under CC BY 4.0**

### 3.2 Diabetes Management

Diabetes, a long-term metabolic condition hitting millions worldwide, calls for fresh delivery ideas to keep blood sugar in check and help folks stick with treatment [56]. Regular insulin shots under the skin can hurt and feel like a hassle, which often messes with follow-through [57]. New drug delivery systems (NDDS), like microneedles and glucose-sensitive setups, bring less invasive, hands-off options to the table [58]. Take dissolving microneedle patches—they slip insulin through the skin, melting away to release it

without any needles or syringes, making things way comfier [59]. Then there's glucose-responsive hydrogels and nanoparticles that track blood sugar swings and dish out insulin on cue, acting a bit like the pancreas's beta cells [60]. These "closed-loop" designs are a big step toward artificial pancreas tech, cutting the need for constant sugar checks and manual shots [61]. One study showed a smart microneedle patch keeping diabetic animals' levels steady for 10 hours [62]. Oral insulin's also in the works, using nanotechnology and pH-smart polymers to shield it from stomach breakdown and boost gut uptake [63]. These leaps could shake up diabetes care, but stuff like stability, scaling, and regulatory green lights still looms large [64]. All in all, NDDS in diabetes shows how they might revamp chronic illness management, lifting outcomes and quality of life.




Figure 5. illustrates two innovative glucose-responsive microneedle patch designs for smart insulin delivery. Panel (a) demonstrates microneedles incorporating hypoxia-sensitive vesicles, where (i) schematically depicts the mechanism of responsive insulin release, and (ii) shows a fluorescence microscopy image (200 μm scale) of vesicle-loaded microneedles with FITC-labeled insulin. Panel (b) presents an alternative approach using a glucose-responsive matrix: (i) explains the release mechanism, (ii) demonstrates in vivo application in a diabetic pig model, (iii) displays the patch's macroscopic appearance, (iv) provides an SEM micrograph (500 μm scale), and (v) shows a fluorescence microscopy image (500 μm scale). Both designs exemplify advanced transdermal delivery strategies that automatically regulate insulin release in response to physiological glucose levels, offering significant potential for improving diabetes management. [153]


### 3.3 Neurological Disorders

Treating neurological disorders such as Alzheimer's, Parkinson's, and epilepsy is particularly difficult because the blood-brain barrier (BBB) blocks most medications from reaching the central nervous system (CNS) [65]. However, novel drug delivery systems (NDDS) provide groundbreaking strategies to either bypass this barrier or enhance drug transport into the brain [66]. One effective method involves nanoparticles engineered with targeting molecules—such as transferrin or angiopep-2—which can slip past the BBB through receptor-mediated transcytosis [67]. For example, in preclinical Alzheimer's studies, polymer-based nanoparticles carrying neuroprotective compounds have successfully reduced amyloid-

beta plaque buildup [68]. Similarly, liposomes have been employed to stabilize dopamine delivery in Parkinson's, significantly improving its absorption in brain tissue [69].

Another innovative approach is intranasal drug administration, which completely avoids the BBB by leveraging the olfactory and trigeminal nerves to shuttle drugs directly from the nasal cavity to the brain [70]. This method has shown potential in epilepsy treatment, where nanoparticle-enhanced nasal sprays and microneedle arrays enable rapid anticonvulsant delivery during seizures [71]. Additionally, researchers are exploring hydrogels infused with stem cells or growth factors to stimulate neural regeneration, offering hope for conditions like stroke-induced brain damage [72].

Despite these breakthroughs, developing NDDS for neurological conditions remains challenging due to the CNS's intricate nature and potential neurotoxicity risks [73]. A major priority in current studies is ensuring sufficient drug concentrations reach the brain without causing harmful systemic effects [74].

**Table 2: Novel Drug Delivery Systems for Neurological Disorders**

| NDDS Type | Neurological Disorder | Mechanism | Reference |
|---|---|---|---|
| Nanoparticles | Alzheimer's Disease | Crosses BBB via receptor-mediated transcytosis to reduce amyloid-beta plaques | [67, 68] |
| Liposomes | Parkinson's Disease | Encapsulates dopamine, enhances stability and brain penetration | [69] |
| Intranasal Delivery | Epilepsy | Bypasses BBB via olfactory/trigeminal pathways for rapid anticonvulsant delivery | [70, 71] |
| Hydrogels | Stroke | Releases growth factors/stem cells to promote neurogenesis and neural repair | [72] |

### 3.4 Infectious Diseases

Infectious diseases triggered by bacterial, viral, or parasitic pathogens demand precise drug delivery systems capable of bypassing resistance mechanisms while effectively targeting infections [75]. Innovative drug delivery platforms (NDDS) have become indispensable in enhancing antimicrobial drug performance, especially as multidrug-resistant (MDR) strains become more prevalent [76].

For instance, nanoparticle-based carriers can transport antibiotics directly to infection sites or even penetrate host cells to attack intracellular pathogens like *Mycobacterium tuberculosis* hiding inside macrophages [77]. Similarly, antiviral therapies benefit from liposomes and polymer-based nanoparticles, which boost the solubility and half-life of drugs such as zidovudine, making them more effective against HIV [78].

Vaccine delivery has also been transformed by technologies like microneedle patches. These patches efficiently target immune cells in the skin, triggering stronger immune responses compared to conventional methods [79]. A prime example is dissolvable microneedle patches for flu vaccines, which generate immunity levels on par with traditional injections while offering greater convenience and patient compliance [80].

Another major challenge in treating bacterial infections is biofilm formation, a key resistance mechanism. NDDS can disrupt biofilms by either concentrating antibiotics at the infection site or integrating specialized agents like quorum-sensing inhibitors to weaken bacterial defences [81].

Globally, NDDS provide adaptable solutions for diseases like malaria and tuberculosis, which disproportionately affect developing regions [82]. For example, liposomal artemisinin formulations increase drug bioavailability and allow less frequent dosing, significantly improving malaria treatment efficacy [83]. Yet, widespread adoption faces hurdles, including high production costs, instability in harsh climates, and ensuring fair distribution to underserved populations [84].

**Table 3: Novel Drug Delivery Systems for Infectious Diseases**

| NDDS Type | Infectious Disease | Mechanism | Reference |
|---|---|---|---|
| Nanoparticles | Tuberculosis | Encapsulates antibiotics, targets intracellular pathogens in macrophages | [77] |
| Liposomes | HIV | Enhances solubility and stability of antiviral drugs (e.g., zidovudine) | [78] |
| Microneedle Patches | Influenza | Delivers vaccines to skin antigen-presenting cells, improves immunogenicity | [79, 80] |
| Antibiofilm NDDS | Bacterial Infections | Delivers high antibiotic concentrations or quorum-sensing inhibitors to disrupt biofilms | [81] |
| Liposomal Formulations | Malaria | Improves bioavailability of antimalarials (e.g., artemisinin), reduces dosing frequency | [83] |

The applications discussed—cancer therapy, diabetes management, neurological disorders, and infectious diseases—illustrate the transformative potential of NDDS across diverse therapeutic areas. However, their widespread adoption is hindered by several technical, regulatory, and economic challenges, which are explored in the following section.

## 4. Challenges in Novel Drug Delivery Systems

While NDDS hold immense promise, their development and clinical implementation face significant obstacles. This section examines the key challenges that must be addressed to fully realize their potential in pharmaceutical sciences.

### 4.1 Scalability and Manufacturing

A major obstacle in the development of novel drug delivery systems (NDDS) is the difficulty of scaling up from small laboratory batches to large-scale industrial production [85]. Many advanced delivery platforms, such as nanoparticles and liposomes, involve intricate synthesis methods that demand strict control over particle size, uniformity, and sterility—factors that significantly drive up manufacturing expenses [86].

For example, producing nanoparticles with uniform size and consistent drug-loading capacity remains a technical challenge, often requiring specialized equipment such as microfluidic devices or high-pressure homogenizers [87]. Microneedle arrays present similar hurdles, as their precise microfabrication is both costly and difficult to replicate on a commercial scale without sacrificing quality [88]. These issues are further complicated by the need to ensure stability during storage and shipping, especially for sensitive biological cargo like proteins or genetic material [89].

Additionally, pharmaceutical companies must comply with Good Manufacturing Practice (GMP) regulations, which enforce strict standards for consistency and quality assurance [90]. Due to these

barriers, only a handful of NDDS—such as liposomal doxorubicin and nanoparticle-bound paclitaxel—have successfully transitioned from research labs to clinical use [91]. To overcome these limitations, researchers are exploring next-generation manufacturing techniques, including continuous-flow synthesis and 3D printing, which could make large-scale production more efficient and cost-effective [92].

### 4.2 Biocompatibility and Safety Concerns

Ensuring the safety of NDDS is a major hurdle in their clinical translation [93]. The materials used in these systems—such as synthetic polymers, metal-based nanoparticles, and carbon nanomaterials—must be carefully designed to avoid toxicity, immune reactions, or organ damage [94].

For instance, while gold nanoparticles are highly effective for targeted drug delivery, their tendency to accumulate in the liver and spleen over time raises concerns about potential long-term toxicity [95]. Similarly, liposomes and hydrogels, though generally safe, can provoke immune responses if their degradation products are not properly metabolized or excreted [96]. The inherent complexity of NDDS, which often incorporate multiple components and active agents, further complicates safety evaluations [97].

Stimuli-responsive systems, in particular, require extensive testing to ensure that they only release their payload under specific conditions, preventing unintended drug leakage or tissue harm [98]. Another concern is the limited understanding of how nanomaterials behave in the body over extended periods, including their clearance pathways and potential genotoxic effects [99].

Regulatory bodies like the FDA and EMA mandate thorough preclinical and clinical testing to assess these risks, which can significantly prolong the approval timeline [100]. To address these challenges, researchers are working to develop more advanced toxicological models and imaging techniques that can better predict the biodistribution and safety of NDDS [101].

**Table 4: Biocompatibility and Safety Concerns of Novel Drug Delivery Systems**

| NDDS Type | Concern | Description | Reference |
|---|---|---|---|
| Nanoparticles | Cytotoxicity | Potential toxicity to cells due to size, surface charge, or material composition | [85] |
| Liposomes | Immune Response | Risk of triggering inflammation or allergic reactions from lipid components | [86] |
| Microneedle Patches | Skin Irritation | Temporary irritation or inflammation at application site | [87] |
| Hydrogels | Degradation Products | Toxicity from breakdown products in the body | [88] |
| All NDDS | Long-Term Safety | Uncertainty of chronic exposure effects (e.g., accumulation in organs) | [86] |

### 4.3 Regulatory Hurdles

The path to clinical approval for novel drug delivery systems (NDDS) presents unique regulatory hurdles that slow their transition from lab to market [102]. Unlike standard medications, NDDS are classified as combination products, requiring evaluation of both the active pharmaceutical ingredient and the delivery platform itself [103]. Regulatory bodies must scrutinize not only the drug's efficacy but also the carrier system's stability, drug release profile, and biological interactions [104].

For instance, nanoparticle-based therapies require exhaustive characterization of physical properties like size, surface charge, and morphology due to their direct impact on drug behavior and safety [105]. Microneedle patches face similar scrutiny, needing to prove reliable skin penetration and controlled drug release across different environmental conditions [106]. This dual assessment frequently results in extended review periods and higher development expenses [107]. Compounding these challenges is the absence of clear regulatory standards specifically for NDDS, as current guidelines were originally designed for traditional drug formulations [108].

The classification of advanced systems like stimulus-responsive hydrogels becomes particularly complex, as they may be regulated as drugs, medical devices, or biologics depending on their design and mechanism [109]. The lack of global regulatory alignment creates additional obstacles for manufacturers pursuing international markets [110]. While some progress has been made—such as the FDA's recent draft guidance on nanomedicines [111]—the current regulatory environment continues to delay patient access to these innovative therapies [112].

**Table 5: Comparison of Regulatory Approval Pathways: Conventional Drugs vs. Novel Drug Delivery Systems (NDDS)**

| Stage | Conventional Drugs | NDDS (Novel Drug Delivery Systems) | References |
|---|---|---|---|
| Preclinical Testing | Drug tested for safety and efficacy in vitro and in vivo. | **Drug + Delivery system tested** for biocompatibility, stability, and release kinetics. | [104] |
| IND (Investigational New Drug) Application | Submitted to regulatory agencies (FDA, EMA, CDSCO, etc.) to begin human trials. | Same as conventional drugs, but requires **additional documentation** on the **delivery system's safety and efficacy**. | [106] |
| Clinical Trials - Phase 1 | Tests drug safety, dosage, and pharmacokinetics in a small group. | Tests **both drug and delivery system** interactions, absorption, and initial safety. | [103] |
| Clinical Trials - Phase 2 | Evaluates efficacy and side effects in a larger patient group. | Assesses **controlled release behavior** and therapeutic effectiveness. | [112] |
| Clinical Trials - Phase 3 | Confirms drug safety and efficacy in a larger population. | Confirms **long-term stability, targeted drug release, and patient response**. | [102] |
| NDA (New Drug Application) Submission | Submitted with clinical trial data for approval. | Submitted with **additional validation** of the **NDDS performance**. | [106] |
| Regulatory Review & Approval | Agencies review safety, efficacy, and manufacturing data. | Includes **extra scrutiny on the delivery system's reliability**. | [105] |

| | | | |
|---|---|---|---|
| Post-Marketing Surveillance | Monitors adverse effects and long-term safety. | Ensures **NDDS maintains stability and therapeutic efficiency over time**. | [108] |

### 4.4 Cost and Accessibility

The high costs associated with NDDS present significant challenges for widespread clinical adoption, particularly in resource-limited settings [113]. The advanced materials and specialized manufacturing techniques required—such as nanoparticle functionalization or precision microneedle fabrication—result in production costs substantially higher than conventional drug formulations [114]. Notable examples include liposomal doxorubicin (Doxil) and nanoparticle albumin-bound paclitaxel (Abraxane), which carry significantly higher price tags than their standard counterparts, restricting their use in lower-income regions [115]. This cost differential exacerbates healthcare disparities, especially for diseases like malaria and tuberculosis that primarily affect developing nations [116].

Additional logistical expenses, such as cold storage requirements for temperature-sensitive formulations, further limit practical implementation in areas with unreliable infrastructure [1].

Potential solutions can be Developing lower-cost biomaterials (e.g., natural polymers instead of synthetic alternatives), Implementing scalable manufacturing technologies like spray drying and Establishing public-private partnerships to subsidize treatments for neglected diseases [4]

However, without substantial policy reforms and increased funding, the high price of NDDS will continue to limit their global impact, leaving many populations without access to these advanced therapies[5]. Overcoming these economic barriers is crucial to ensure equitable healthcare innovation worldwide.




**Figure 6. Cost Comparison of Conventional Drugs and Novel Drug Delivery Systems. [114]**

The challenges outlined—scalability, biocompatibility, regulatory hurdles, and cost—highlight the multifaceted barriers facing NDDS. Overcoming these obstacles requires interdisciplinary collaboration and innovative strategies, which are discussed in the next section.

## 5. Future Directions in Novel Drug Delivery Systems

The future of NDDS lies in leveraging emerging technologies and addressing current limitations to enhance their clinical impact. This section explores key trends and strategies that could shape the next generation of drug delivery platforms.

### 5.1 Integration with Digital Technologies

The integration of NDDS with cutting-edge digital technologies like wearable devices and artificial intelligence (AI) is revolutionizing personalized medicine [5]. Advanced smart delivery systems now incorporate biosensors that track physiological markers in real-time, enabling dynamic drug release adjustments [6]. A prime example includes glucose-responsive microneedle patches that automate insulin delivery for diabetes patients, combined with AI-driven algorithms that personalize dosing regimens based on continuous health monitoring [7]. These innovations significantly enhance treatment precision while minimizing patient burden, leading to better therapeutic outcomes and medication compliance [8].

This digital integration also enables remote patient monitoring through telemedicine platforms, particularly valuable for managing chronic conditions in rural or underserved communities [9]. However, several challenges must be resolved, including data security concerns, device durability issues, and the development of appropriate regulatory standards for digital-pharmaceutical hybrids [10]. The fusion of NDDS with digital health tools marks a transformative shift toward intelligent, patient-focused treatment solutions [11].




**Figure 7. Integration of Microneedles with Digital Technology for Closed-Loop Drug Delivery.[154] licensed under CC BY 4.0**

### 5.2 Bioinspired and Biomimetic Systems

Bioinspired NDDS that mimic biological systems are emerging as powerful solutions for enhancing drug delivery efficiency and safety [12]. Researchers are developing carriers that replicate natural structures like red blood cells or viral particles, enabling them to bypass immune defenses and penetrate target tissues

more effectively [13]. These biomimetic systems leverage millions of years of evolutionary refinement to overcome biological barriers including the blood-brain barrier and mucosal membranes [14].

Among the most promising developments are natural nanocarriers like exosomes - cell-derived extracellular vesicles that show remarkable potential as drug delivery vehicles [15]. These endogenous particles possess innate tissue-targeting abilities and can transport delicate biological cargo (including RNA and proteins) across normally impenetrable barriers [16]. Scientists have successfully engineered exosomes to deliver diverse therapeutics ranging from chemotherapy agents to CRISPR gene-editing components, offering a potentially safer alternative to artificial carriers [42].

Parallel innovations include hydrogel systems that recreate the body's extracellular matrix environment, providing both structural support for tissue regeneration and controlled release of growth factors [87]. Such biologically harmonious approaches not only improve delivery efficiency but also minimize adverse reactions by working with the body's natural processes [19]. Current limitations include difficulties in scaling up exosome production and standardizing isolation methods [63], though progress in synthetic biology and nanotechnology promises solutions that could establish bioinspired systems as fundamental therapeutic platforms [105].

**Table 6: Comparison of Synthetic Nanoparticles and Exosomes as Drug Delivery Vehicles**

| Feature | Synthetic Nanoparticles | Exosomes | Refrences |
|---|---|---|---|
| Origin | Artificially engineered | Naturally derived from cells | [12] |
| Structure | Core-shell, polymeric, or lipid-based spheres | Lipid bilayer vesicles with surface proteins | [13] |
| Size Range | 10–500 nm | 30–150 nm | [14] |
| Composition | Polymers, lipids, inorganic materials (gold, silica) | Phospholipids, proteins, nucleic acids | [15] |
| Surface Modification | Functionalized with ligands, PEG, antibodies | Naturally decorated with cellular proteins | [16] |
| Biocompatibility | Can trigger immune response | High, due to natural origin | [42] |
| Stability | Highly stable | Less stable, sensitive to environmental factors | [63] |
| Drug Loading Capacity | High, tunable encapsulation | Moderate, limited by natural structure | [87] |
| Targeting Mechanism | Actively targeted via surface modifications | Naturally targets specific cells via surface markers | [105] |
| Manufacturing Process | Scalable, controlled synthesis | Challenging, requires isolation from cells | [12] |
| Immunogenicity | Possible immune response | Low, due to endogenous origin | [13] |
| Degradation | Controlled biodegradability | Biodegradable via natural pathways | [14] |

| | | | |
|---|---|---|---|
| Examples | Liposomes, polymeric nanoparticles, gold nanoparticles | Exosome-derived drug carriers, RNA-loaded vesicles | [15] |

### 5.3 Sustainable and Green Technologies

The pharmaceutical industry is increasingly prioritizing sustainability in NDDS design, addressing both environmental concerns and production economics [91]. Researchers are turning to biodegradable materials like chitosan (from shellfish) and alginate (from seaweed) that offer eco-friendly alternatives to conventional polymers [28]. These natural substances safely break down in biological and environmental systems, alleviating worries about persistent accumulation of synthetic nanomaterials [74]. Green manufacturing techniques, such as plant-based nanoparticle synthesis, are reducing dependence on toxic chemicals and energy-intensive processes [13]. For example, plant-derived silver nanoparticles demonstrate effective antimicrobial properties while being more environmentally sustainable and cost-efficient than traditionally produced counterparts [50]. Such eco-conscious methods not only support global sustainability initiatives but also enhance the feasibility of large-scale NDDS production for use in developing regions [33].

Additive manufacturing technologies like 3D printing are enabling fabrication of customized drug delivery devices (e.g., microneedles, implants) using biodegradable polymers [99]. This approach allows for both personalized medicine solutions and reduced material waste during production [67]. However, natural materials often require modification to match the mechanical properties and stability of synthetic alternatives [12], necessitating collaboration between pharmaceutical experts, materials scientists, and regulators to successfully implement sustainable solutions [88].

## 6. Conclusion

The pharmaceutical landscape has been revolutionized by Novel Drug Delivery Systems (NDDS), which overcome the shortcomings of conventional approaches through innovative technologies like nanoparticles, liposomes, microneedles, and smart polymers [1-3,11]. These cutting-edge platforms enable precise drug targeting, controlled release profiles, and improved patient adherence across various therapeutic areas [5,8,118]. In cancer treatment, nanoparticles utilize the EPR effect to concentrate chemotherapy drugs at tumor sites while reducing systemic side effects [1,5,49], while liposomal formulations such as Doxil minimize cardiac toxicity without compromising efficacy [2,31]. Transdermal microneedle patches have transformed diabetes care through painless insulin administration [3,10], and intelligent glucose-responsive hydrogels mimic natural pancreatic function [35,107,109]. NDDS also facilitate breakthrough treatments for neurological disorders by transporting drugs across the blood-brain barrier [9,67,68] and enable effective delivery of delicate biologics like gene therapies [8,9]. However, several challenges hinder the widespread adoption of these advanced systems. Manufacturing complexities involving precise nanoparticle synthesis and sterilization processes result in high production costs [85,87,88], while safety concerns regarding nanomaterial accumulation and immune reactions demand extensive testing [55,56,95]. Current regulatory systems, designed for traditional drugs, face difficulties evaluating combination products, leading to prolonged approval processes [102,104,108]. Economic and logistical barriers further limit global access, particularly in developing regions where expensive cold-chain storage requirements create distribution challenges [1,8,113,115]. Future progress depends on integrating emerging technologies with sustainable solutions. Digital health tools like wearable

sensors combined with AI could enable real- time treatment adjustments [6,7], while nature-inspired exosome carriers may offer safer alternatives to synthetic nanoparticles [149,150]. Environmentally friendly production methods using biodegradable materials could reduce costs and ecological impact [28,91]. Realizing this potential requires collaborative efforts to standardize regulations [101,111], optimize manufacturing through innovations like 3D printing [92], and establish funding mechanisms for global accessibility [4,116]. As NDDS continue to evolve, they promise to deliver more personalized, effective, and equitable treatments, fundamentally transforming patient care worldwide [117,147]. Their successful implementation will depend on addressing current limitations while maintaining focus on clinical relevance and patient needs [35,93].

**REFERENCES**

1. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. "Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review." J Control Release. 2000;65(1-2):271-284.
2. Allen TM, Cullis PR. "Liposomal drug delivery systems: from concept to clinical applications." Adv Drug Deliv Rev. 2013;65(1):36-48.
3. Prausnitz MR, Langer R. "Transdermal drug delivery." Nat Biotechnol. 2008;26(11):1261-1268.
4. Torchilin VP. "Recent advances with liposomes as pharmaceutical carriers." Nat Rev Drug Discov. 2005;4(2):145-160.
5. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. "Nanocarriers as an emerging platform for cancer therapy." Nat Nanotechnol. 2007;2(12):751-760.
6. Yu MK, Park J, Jon S. "Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy." Theranostics. 2012;2(1):3-44.
7. Kim BY, Rutka JT, Chan WC. "Nanomedicine." N Engl J Med. 2010;363(25):2434-2443.
8. Mitragotri S, Burke PA, Langer R. "Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies." Nat Rev Drug Discov. 2014;13(9):655-672.
9. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. "Nanoparticles in medicine: therapeutic applications and developments." Clin Pharmacol Ther. 2008;83(5):761-769.
10. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. "Microneedle-based vaccines." Curr Top Microbiol Immunol. 2009;333:369-393.
11. Peppas NA, Hilt JZ, Khademhosseini A, Langer R. "Hydrogels in biology and medicine: from molecular principles to bionanotechnology." Adv Mater. 2006;18(11):1345-1360.
12. Mo R, Jiang T, DiSanto R, Tai W, Gu Z. "ATP-triggered anticancer drug delivery." Nat Commun. 2014;5:3364.
13. Jain RK, Stylianopoulos T. "Delivering nanomedicine to solid tumors." Nat Rev Clin Oncol. 2010;7(11):653-664.
14. Davis ME, Chen ZG, Shin DM. "Nanoparticle therapeutics: an emerging treatment modality for cancer." Nat Rev Drug Discov. 2008;7(9):771-782.
15. Bangham AD, Standish MM, Watkins JC. "Diffusion of univalent ions across the lamellae of swollen phospholipids." J Mol Biol. 1965;13(1):238-252.
16. Wichterle O, Lím D. "Hydrophilic gels for biological use." Nature. 1960;185(4706):117-118.
17. Langer R, Tirrell DA. "Designing materials for biology and medicine." Nature. 2004;428(6982):487-492.

18. Farokhzad OC, Langer R. "Impact of nanotechnology on drug delivery." ACS Nano. 2009;3(1):16-20.
19. Gillies ER, Fréchet JM. "pH-responsive copolymer assemblies for controlled release of doxorubicin." Bioconjug Chem. 2005;16(2):361-368.
20. Moghimi SM, Hunter AC, Murray JC. "Nanomedicine: current status and future prospects." FASEB J. 2005;19(3):311-330.
21. De Jong WH, Borm PJ. "Drug delivery and nanoparticles: applications and hazards." Int J Nanomedicine. 2008;3(2):133-149.
22. Duncan R. "Polymer conjugates as anticancer nanomedicines." Nat Rev Cancer. 2006;6(9):688-701.
23. Petros RA, DeSimone JM. "Strategies in the design of nanoparticles for therapeutic applications." Nat Rev Drug Discov. 2010;9(8):615-627.
24. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. "Biodegradable polymeric nanoparticles as drug delivery devices." J Control Release. 2001;70(1-2):1-20.
25. Bae YH, Park K. "Targeted drug delivery to tumors: myths, reality and possibility." J Control Release. 2011;153(3):198-205.
26. Kataoka K, Harada A, Nagasaki Y. "Block copolymer micelles for drug delivery: design, characterization and biological significance." Adv Drug Deliv Rev. 2001;47(1):113-131.
27. Couvreur P, Vauthier C. "Nanotechnology: intelligent design to treat complex disease." Pharm Res. 2006;23(7):1417-1450.
28. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. "Biodegradable long-circulating polymeric nanospheres." Science. 1994;263(5153):1600-1603.
29. Lasic DD. "Liposomes: from physics to applications." Elsevier. 1993.
30. Gregoriadis G. "Engineering liposomes for drug delivery: progress and problems." Trends Biotechnol. 1995;13(12):527-537.
31. Barenholz Y. "Doxil®—the first FDA-approved nano-drug: lessons learned." J Control Release. 2012;160(2):117-134.
32. Needham D, Dewhirst MW. "The development and testing of a new temperature-sensitive drug delivery system." Adv Drug Deliv Rev. 2001;53(3):285-305.
33. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. "Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors." Pharmacol Rev. 1999;51(4):691-743.
34. Kim S, Kim JH, Jeon O, Kwon IC, Park K. "Engineered polymers for advanced drug delivery." Eur J Pharm Biopharm. 2009;71(3):420-430.
35. Hoffman AS. "Hydrogels for biomedical applications." Adv Drug Deliv Rev. 2002;54(1):3-12.
36. Caldorera-Moore M, Peppas NA. "Micro- and nanotechnologies for intelligent and responsive biomaterial-based medical systems." Adv Drug Deliv Rev. 2009;61(15):1391-1401.
37. Kost J, Langer R. "Responsive polymeric delivery systems." Adv Drug Deliv Rev. 2001;46(1-3):125-148.
38. Kim SW, Bae YH, Okano T. "Hydrogels: swelling, drug loading, and release." Pharm Res. 1992;9(3):283-290.
39. Henry BD, Neill DR, Becker KA, et al. "Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections." Sci Transl Med. 2015;7(316):316ra192.

40. Donnelly RF, Singh TR, Woolfson AD. "Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety." Drug Deliv. 2010;17(4):187-207.
41. Larrañeta E, Lutton RE, Woolfson AD, Donnelly RF. "Microneedle arrays as transdermal and intradermal drug delivery systems." Mater Sci Eng R Rep. 2016;104:1-32.
42. Sullivan CO, Birkinshaw C. "In vitro degradation of insulin-loaded poly(n-butylcyanoacrylate) nanoparticles." Biomaterials. 2004;25(18):4375-4382.
43. Yeo Y, Park K. "Control of encapsulation efficiency and initial burst in polymeric microparticle systems." Arch Pharm Res. 2004;27(1):1-12.
44. Chen H, Zhang H, Gu Z, et al. "Nanotechnology in drug delivery: opportunities and challenges." Nanomedicine. 2016;11(19):2527-2531.
45. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. "Nanomedicine—challenge and perspectives." Angew Chem Int Ed Engl. 2009;48(5):872-897.
46. El-Sayed IH, Huang X, El-Sayed MA. "Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles." Cancer Lett. 2006;239(1):129-135.
47. Huang X, Jain PK, El-Sayed IH, El-Sayed MA. "Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy." Nanomedicine. 2007;2(5):681-693.
48. Dreaden EC, Austin LA, Mackey MA, El-Sayed MA. "Size matters: gold nanoparticles in targeted cancer therapy." J Drug Target. 2012;20(8):669-679.
49. Schroeder A, Heller DA, Winslow MM, et al. "Treating metastatic cancer with nanotechnology." Nat Rev Cancer. 2011;12(1):39-50.
50. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. "Factors affecting the clearance and biodistribution of polymeric nanoparticles." Mol Pharm. 2008;5(4):505-515.
51. Knop K, Hoogenboom R, Fischer D, Schubert US. "Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives." Angew Chem Int Ed Engl. 2010;49(36):6288-6308.
52. Harris JM, Chess RB. "Effect of pegylation on pharmaceuticals." Nat Rev Drug Discov. 2003;2(3):214-221.
53. Veronese FM, Pasut G. "PEGylation, successful approach to drug delivery." Drug Discov Today. 2005;10(21):1451-1458.
54. Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. "Nanoparticle PEGylation for imaging and therapy." Nanomedicine. 2011;6(4):715-728.
55. Oberdörster G. "Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles." Environ Health Perspect. 2005;113(7):823-839.
56. Nel A, Xia T, Mädler L, Li N. "Toxic potential of materials at the nanolevel." Science. 2006;311(5761):622-627.
57. Lewinski N, Colvin V, Drezek R. "Cytotoxicity of nanoparticles." Small. 2008;4(1):26-49.
58. Auffan M, Rose J, Bottero JY, Lowry GV, Jolivet JP, Wiesner MR. "Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective." Nat Nanotechnol. 2009;4(10):634-641.
59. Buzea C, Pacheco II, Robbie K. "Nanomaterials and nanoparticles: sources and toxicity." Biointerphases. 2007;2(4):MR17-MR71.
60. Hagens WI, Oomen AG, de Jong WH, Cassee FR, Sips AJ. "What do we (need to) know about the kinetic properties of nanoparticles in the body?" Regul Toxicol Pharmacol. 2007;49(3):217-229.

61. Sanhai WR, Sakamoto JH, Canady R, Ferrari M. "Seven challenges for nanomedicine." Nat Nanotechnol. 2008;3(5):242-244.
62. Wagner V, Dullaart A, Bock AK, Zweck A. "The emerging nanomedicine landscape." Nat Biotechnol. 2006;24(10):1211-1217.
63. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. "The big picture on nanomedicine: the state of investigational and approved nanomedicine products." Nanomedicine. 2013;9(1):1-14.
64. Tinkle S, McNeil SE, Mühlebach S, et al. "Nanomedicines: addressing the scientific and regulatory gap." Ann N Y Acad Sci. 2014;1313:35-56.
65. Ventola CL. "The nanomedicine revolution: part 1: emerging concepts." P T. 2012;37(9):512-525.
66. Kim TH, Lee S, Chen X. "Nanomedicines for cancer therapy: current status, challenges, and future prospects." Ther Deliv. 2013;4(6):617-620.
67. Desai N. "Challenges in development of nanoparticle-based therapeutics." AAPS J. 2012;14(2):282-295.
68. Duncan R, Gaspar R. "Nanomedicine(s) under the microscope." Mol Pharm. 2011;8(6):2101-2141.
69. Fadel TR, Farrell DF, Friedersdorf LE, et al. "Toward the responsible development and commercialization of nanotechnology-based pharmaceuticals." Nanomedicine. 2015;11(6):1485-1495.
70. Bawa R. "Nanotechnology patents and challenges." Curr Pharm Biotechnol. 2008;9(6):495-502.
71. Hafner A, Lovrić J, Lakoš GP, Pepić I. "Nanotherapeutics in the EU: an overview on current state and future directions." Int J Nanomedicine. 2014;9:1005-1023.
72. Moghimi SM, Patel HM. "Serum-mediated recognition and clearance of liposomes: opsonization and phagocytosis." Adv Drug Deliv Rev. 1998;32(1-2):45-60.
73. Storm G, Belliot SO, Daemen T, Lasic DD. "Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system." Adv Drug Deliv Rev. 1995;17(1):31-48.
74. Owens DE 3rd, Peppas NA. "Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles." Int J Pharm. 2006;307(1):93-102.
75. Champion JA, Katare YK, Mitragotri S. "Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers." J Control Release. 2007;121(1-2):3-9.
76. Decuzzi P, Pasqualini R, Arap W, Ferrari M. "Intravascular delivery of particulate systems: does geometry really matter?" Pharm Res. 2009;26(1):235-243.
77. Geng Y, Dalhaimer P, Cai S, et al. "Shape effects of filaments versus spherical particles in flow and drug delivery." Nat Nanotechnol. 2007;2(4):249-255.
78. Chithrani BD, Ghazani AA, Chan WC. "Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells." Nano Lett. 2006;6(4):662-668.
79. Gratton SE, Ropp PA, Pohlhaus PD, et al. "The effect of particle design on cellular internalization pathways." Proc Natl Acad Sci U S A. 2008;105(33):11613-11618.
80. Perry JL, Herlihy KP, Napier ME, Desimone JM. "PRINT: a novel platform toward shape and size specific nanoparticle theranostics." Acc Chem Res. 2011;44(10):990-998.
81. Rolland JP, Maynor BW, Euliss LE, Exner AE, Denison GM, DeSimone JM. "Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials." J Am Chem Soc. 2005;127(28):10096-10100.

82. Kim D, Kim J, Park YI, Lee N, Hyeon T. "Recent development of inorganic nanoparticles for biomedical imaging." ACS Cent Sci. 2018;4(3):324-336.
83. Anselmo AC, Mitragotri S. "Nanoparticles in the clinic." Bioeng Transl Med. 2016;1(1):10-29.
84. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. "Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date." Pharm Res. 2016;33(10):2373-2387.
85. Wilhelm S, Tavares AJ, Dai Q, et al. "Analysis of nanoparticle delivery to tumours." Nat Rev Mater. 2016;1:16014.
86. Blanco E, Shen H, Ferrari M. "Principles of nanoparticle design for overcoming biological barriers to drug delivery." Nat Biotechnol. 2015;33(9):941-951.
87. Shi J, Votruba AR, Farokhzad OC, Langer R. "Nanotechnology in drug delivery and tissue engineering: from discovery to applications." Nano Lett. 2010;10(9):3223-3230.
88. Zhang Y, Chan HF, Leong KW. "Advanced materials and processing for drug delivery: the past and the future." Adv Drug Deliv Rev. 2013;65(1):104-120.
89. Liu Z, Tabakman S, Welsher K, Dai H. "Carbon nanotubes in biology and medicine: in vitro and in vivo detection, imaging and drug delivery." Nano Res. 2009;2(2):85-120.
90. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. "Targeted polymeric therapeutic nanoparticles: design, development and clinical translation." Chem Soc Rev. 2012;41(7):2971-3010.
91. Wang AZ, Langer R, Farokhzad OC. "Nanoparticle delivery of cancer drugs." Annu Rev Med. 2012;63:185-198.
92. Jain KK. "Advances in the field of nanooncology." BMC Med. 2010;8:83.
93. Ferrari M. "Frontiers of nanotechnology in medicine." Nat Rev Cancer. 2005;5(3):161-171.
94. Davis ME. "The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic." Mol Pharm. 2009;6(3):659-668.
95. Hrkach J, Von Hoff D, Mukkaram Ali M, et al. "Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile." Sci Transl Med. 2012;4(128):128ra39.
96. Von Hoff DD, Mita MM, Ramanathan RK, et al. "Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors." Invest New Drugs. 2016;34(3):300-309.
97. Kim ES, Kim SY, Ha IH, Lee YJ, et al. "Nanoparticle-based drug delivery systems: an updated review." J Pharm Investig. 2021;51(1):1-17.
98. Tong R, Chiang HH, Kohane DS. "Photoswitchable nanoparticles for in vivo cancer chemotherapy." Proc Natl Acad Sci U S A. 2013;110(47):19048-19053.
99. Choi HS, Liu W, Misra P, et al. "Renal clearance of quantum dots." Nat Biotechnol. 2007;25(10):1165-1170.
100. Lee JH, Yeo Y. "Controlled drug release from pharmaceutical nanocarriers." Chem Eng Sci. 2015;125:75-84.
101. Prausnitz MR, Gill HS, Park JH. "Microneedles for drug delivery." Annu Rev Chem Biomol Eng. 2015;6:363-381.
102. Kim YC, Park JH, Prausnitz MR. "Microneedles for drug and vaccine delivery." Adv Drug Deliv Rev. 2012;64(14):1547-1568.

103. Sullivan SP, Koutsonanos DG, Del Pilar Martin M, et al. "Dissolving polymer microneedle patches for influenza vaccination." Nat Med. 2010;16(8):915-920.
104. Norman JJ, Choi SO, Tong NT, Auriac CR, Prausnitz MR. "Stability of influenza vaccine coated onto microneedles." Biomaterials. 2013;34(13):3222-3230.
105. DeMuth PC, Min Y, Huang B, et al. "Polymer multilayer tattooing for enhanced DNA vaccination." Nat Mater. 2013;12(4):367-376.
106. Gu Z, Aimetti AA, Wang Q, et al. "Injectable nano-network for glucose-mediated insulin delivery." ACS Nano. 2013;7(5):4194-4201.
107. Yu J, Zhang Y, Ye Y, et al. "Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery." Proc Natl Acad Sci U S A. 2015;112(27):8260-8265.
108. Wang J, Ye Y, Yu J, et al. "Core-shell microneedle gel for self-regulated insulin delivery." ACS Nano. 2018;12(3):2466-2473.
109. Chen W, Tian R, Xu C, et al. "Microneedle-array patches with pH-triggered degradation for glucose-responsive insulin delivery." Adv Mater. 2017;29(36):1701620.
110. Bachelder EM, Beaudette TT, Broaders KE, Fréchet JM, Albrecht MT, Mateczun AJ. "In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants." Mol Pharm. 2010;7(3):826-835.
111. Kopeček J. "Hydrogel biomaterials: a smart future?" Biomaterials. 2007;28(34):5185-5192.
112. Qiu Y, Park K. "Environment-sensitive hydrogels for drug delivery." Adv Drug Deliv Rev. 2001;53(3):321-339.
113. Vermonden T, Censi R, Hennink WE. "Hydrogels for protein delivery." Chem Rev. 2012;112(5):2853-2888.
114. Li J, Mooney DJ. "Designing hydrogels for controlled drug delivery." Nat Rev Mater. 2016;1:16071.
115. Hoare TR, Kohane DS. "Hydrogels in drug delivery: progress and challenges." Polymer. 2008;49(8):1993-2007.
116. Slaughter BV, Khurshid SS, Fisher OZ, Khademhosseini A, Peppas NA. "Hydrogels in regenerative medicine." Adv Mater. 2009;21(32-33):3307-3329.
117. Tibbitt MW, Dahlman JE, Langer R. "Emerging frontiers in drug delivery." J Am Chem Soc. 2016;138(3):704-717.
118. Langer R. "New methods of drug delivery." Science. 1990;249(4976):1527-1533.
119. Siepmann J, Siegel RA, Rathbone MJ. "Fundamentals and applications of controlled release drug delivery." Springer. 2012.
120. Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. "Polymeric systems for controlled drug release." Chem Rev. 1999;99(11):3181-3198.
121. Park K. "Controlled drug delivery systems: past forward and future back." J Control Release. 2014;190:3-8.
122. Grattoni A, Fine D, Ziemys A, et al. "Nanochannel technology for constant delivery of chemotherapeutics." Curr Pharm Biotechnol. 2011;12(10):1631-1640.
123. Rapoport N. "Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery." Prog Polym Sci. 2007;32(8-9):962-990.

124. Meng F, Zhong Z, Feijen J. "Stimuli-responsive polymersomes for programmed drug delivery." Biomacromolecules. 2009;10(2):197-209.
125. Ganta S, Devalapally H, Shahiwala A, Amiji M. "A review of stimuli-responsive nanocarriers for drug and gene delivery." J Control Release. 2008;126(3):187-204.
126. Mura S, Nicolas J, Couvreur P. "Stimuli-responsive nanocarriers for drug delivery." Nat Mater. 2013;12(11):991-1003.
127. Karimi M, Ghasemi A, Sahandi Zangabad P, et al. "Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems." Chem Soc Rev. 2016;45(5):1457-1501.
128. Stuart MA, Huck WT, Genzer J, et al. "Emerging applications of stimuli-responsive polymer materials." Nat Mater. 2010;9(2):101-113.
129. De Las Heras Alarcón C, Pennadam S, Alexander C. "Stimuli responsive polymers for biomedical applications." Chem Soc Rev. 2005;34(3):276-285.
130. Cabane E, Zhang X, Langowska K, Papadakis CM, Haag R. "Stimuli-responsive polymers and their applications in nanomedicine." Biointerphases. 2012;7(1-4):9.
131. Rapoport N, Pitt WG, Sun H, Nelson JL. "Drug delivery in polymeric micelles: from in vitro to in vivo." J Control Release. 2003;91(1-2):85-95.
132. [132] Bae Y, Fukushima S, Harada A, Kataoka K. "Design of environment-sensitive supramolecular assemblies for intracellular drug delivery." Angew Chem Int Ed Engl. 2003;42(38):4640-4643.
133. Discher DE, Eisenberg A. "Polymer vesicles." Science. 2002;297(5583):967-973.
134. Torchilin VP. "Micellar nanocarriers: pharmaceutical perspectives." Pharm Res. 2007;24(1):1-16.
135. Adams ML, Lavasanifar A, Kwon GS. "Amphiphilic block copolymers for drug delivery." J Pharm Sci. 2003;92(7):1343-1355.
136. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. "Block copolymer micelles: preparation, characterization and application in drug delivery." J Control Release. 2005;109(1-3):169-188.
137. Rösler A, Vandermeulen GW, Klok HA. "Advanced drug delivery devices via self-assembly of amphiphilic block copolymers." Adv Drug Deliv Rev. 2012;64(Suppl):270-279.
138. Chen H, Kim S, Li L, et al. "Release of hydrophobic molecules from polymer micelles into cell membranes revealed by Förster resonance energy transfer imaging." Proc Natl Acad Sci U S A. 2008;105(18):6596-6601.
139. Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. "Theranostic nanomedicine." Acc Chem Res. 2011;44(10):1029-1038.
140. Janib SM, Moses AS, MacKay JA. "Imaging and drug delivery using theranostic nanoparticles." Adv Drug Deliv Rev. 2010;62(11):1052-1063.
141. Kelkar SS, Reineke TM. "Theranostics: combining imaging and therapy." Bioconjug Chem. 2011;22(10):1879-1903.
142. Xie J, Lee S, Chen X. "Nanoparticle-based theranostic agents." Adv Drug Deliv Rev. 2010;62(11):1064-1079.
143. Kim K, Kim JH, Park H, et al. "Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous diagnosis, drug delivery, and therapeutic monitoring." J Control Release. 2010;146(2):219-227.
144. Lammers T, Kiessling F, Hennink WE, Storm G. "Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress." J Control Release. 2012;161(2):175-187.

145. Bae YH, Park K. "Advanced drug delivery: perspectives and prospects." J Control Release. 2011;153(3):196-197.
146. Holzapfel BM, Reichert JC, Schantz JT, et al. "How smart do biomaterials need to be? A translational science and clinical point of view." Adv Drug Deliv Rev. 2013;65(4):581-603.
147. Yoo JW, Irvine DJ, Discher DE, Mitragotri S. "Bio-inspired, bioengineered and biomimetic drug delivery carriers." Nat Rev Drug Discov. 2011;10(7):521-535.
148. Hu CM, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. "Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform." Proc Natl Acad Sci U S A. 2011;108(27):10980-10985.
149. Théry C, Zitvogel L, Amigorena S. "Exosomes: composition, biogenesis and function." Nat Rev Immunol. 2002;2(8):569-579.
150. Kalluri R, LeBleu VS. "The biology, function, and biomedical applications of exosomes." Science. 2020;367(6478):6977.
151. Li Y, Zhang Y, Ye Y, Zhang Y. “Microneedle-array patches loaded with hypoxia-sensitive vesicles for fast glucose-responsive insulin delivery systems.” Proc Natl Acad Sci U S A. 2015;112(27):8260-8265.
152. Cheng-Sánchez I, Moya-Utrera F, Porras-Alcalá P, López-Romero JM, Sarabia F. “Antibody-drug conjugates containing payloads from marine origin for cancer therapy.” Mar Drugs. 2022;20(8):494.
153. Zhang X, Wang Y, Zhu D, Liu Y, Tao Y. “Smart microneedles for therapy and diagnosis.” Res Sci Transl Med. 2020;2020:7462915.
154. Kim G, Ahn HS, Ulloa JC, Gao W. “Microneedle sensors for dermal interstitial fluid analysis for drug delivery.” Med-X. 2024;2(1):15.
155. Shah S, Singh S. “Smart microneedles integrated with AI for real-time glucose monitoring and insulin delivery.” Bio-Des Manuf. 2024;7(4):1-12.